When was Orf Genetics founded?

Orf Genetics was founded in 2001 and raised its 1st funding round 19 years after it was founded.

Where is Orf Genetics located?

Orf Genetics is headquartered in Kopavogur, Iceland.

Who is the current CEO of Orf Genetics?

Frosti Olafsson of Orf Genetics.

How many employees does Orf Genetics have?

As of Sep 30, 2026, the latest employee count at Orf Genetics is 26.

Is Orf Genetics a funded company?

Orf Genetics is a funded company, having raised a total of $5.87M across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Oct 01, 2020.

When was the latest funding round of Orf Genetics?

Orf Genetics' latest funding was a $***** Series A round on Sep 10, 2025, with participation from 0 investor.

Where does Orf Genetics rank among its competitors?

Orf Genetics ranks 2nd amongst 90 active competitors, of which 19 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Laigo Biotechnology, which secured $6.36M in Mar, 2026.

Who are the top competitors of Orf Genetics?

Orf Genetics' top competitors include Qkine, Laigo Biotechnology and Core Biogenesis. Among them, Laigo Biotechnology secured the most recent funding round in March, 2026.

Orf Genetics - 2026 Company Profile, Team, Funding & Competitors

Company Details

ORF Genetics is developing recombinant protein technology. The company is focusing on growth factors and cytokines and has developed proprietary products called bioeffects, isokine, and thaumatin among others. Bioeffects is the recombinant protein which is used for medical research, stem cell technology, and skincare. Orfeus is produced from barley grain which is used in developing the growth factor and cytokine using the high throughput production.

Website: www.orfgenetics.com/
Email ID: *****@orfgenetics.com
Phone Number: +354 **********

Key Metrics

Founded Year

2001

Location

Kopavogur, Iceland

Stage

Series A

Total Funding

$5.87M in 3 rounds

Latest Funding Round

Series A, Sep 10, 2025, $*****

Investors

EIC Fund & 1 more

Ranked

2^nd among 90 active competitors

Employee Count

26 as on Sep 30, 2026

Similar Companies

Qkine & 91 more

View Orf Genetics' full profile

Orf Genetics has raised a total funding of $5.87M over 3 rounds. Its first funding round was on Oct 01, 2020. Orf Genetics has 2 institutional investors.

Here is the list of recent funding rounds of Orf Genetics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 10, 2025	7241691	Series A	1478974	4413451	8871437	9761760
Sep 30, 2022	1591293	Grant (prize money)	8715116	9647781	8684017	EIC Fund
Oct 01, 2020	7383481	Grant (prize money)	6730847	6316508	2204645	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Orf Genetics's funding rounds and investors

Orf Genetics' employee count trend

Orf Genetics has 26 employees as of Sep 26. Here is Orf Genetics's employee count trend over the years:

Uncover Orf Genetics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orf Genetics include Qkine, Laigo Biotechnology and Core Biogenesis. Here is the list of Top 10 competitors of Orf Genetics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Qkine 2016, Cambridge (United Kingdom), Series A	Developer of animal-free growth factors for life science applications	$8.15M	Parkwalk, Downing Ventures & 18 others	60/100
2nd	Orf Genetics 2001, Kopavogur (Iceland), Series A	Developer of recombinant protein technology	$5.87M	EIC Fund, Europa	40/100
3rd	Laigo Biotechnology 2023, Utrecht (Netherlands), Seed	Developer of targeted protein degradation technology for therapeutic applications	$19.8M	Kurma Partners, Curie Capital & 8 others	48/100
4th	Core Biogenesis 2020, Paris (France), Series A	Provider of UBaaS platform for recombinant protein bioproduction	$14.1M	Plug and Play Tech Center, Entrepreneurs First ... & 6 others	47/100
5th	Future Fields 2017, Edmonton (Canada), Series A	Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins	$21.6M	Bee Partners, Toyota Ventures & 21 others	43/100
6th	KAICO 2018, Fukuoka (Japan), Series B	Manufacturer of portfolio of proteins and other biological cytokines and enzymes	$8.15M	ITOCHU Technology Ventures, Tokyo Century ... & 8 others	38/100
7th	Xias Bio 2020, United States, Seed	Developer of recombinant proteins	$5.23M	IndieBio, SOSV & 4 others	38/100
8th	MarraBio 2011, Newcastle Upon Tyne (United Kingdom), Seed	Biotechnology research company that provides bacterial protein polymers	-	Maven Capital Partners, Northstar Ventures ... & 2 others	38/100
9th	Hunan Zhongsheng Quanpeptide Biotechnology 2017, Zhuzhou (China), Series B	Developer of peptide discovery technology, peptide libraries, and related research products	$47.9M	CDH, Xjsci & 7 others	37/100
10th	Algenex 2005, Madrid (Spain), Series B	Developer of recombinant biologics for animal and human health	$13.3M	Columbus Venture Partners, Vita Advisory & 1 others	35/100